Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DP303c vs trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer
CTR20240245Phase 3Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jan 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of DP303c in breast cancer, sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Jan 2024; status: completed.
02
Drugs
DP303c
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20240245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240245.